These results have far-reaching implications for the treatment of Alzheimer's disease, MCI, and SCI; for personalized programs that may enhance pharmaceutical efficacy; and for personal identification of ApoE genotype. The gene discussed is APOE; the disease is early-onset autosomal dominant Alzheimer disease.